ASP Isotopes expects JSE dual listing Aug 27; Renergen acquisition on track for Q3 2025

ASP Isotopes Inc.

JSE dual listing expected to begin Aug 27, 2025; company retains Nasdaq primary listing.
Renergen acquisition approved by 99.8% of Renergen shareholders; expected close Q3 2025.
Combined company targets over $300M EBITDA by 2030 from isotopes, helium, and LNG.
Inducement awards: 400,000 restricted shares to EVP Donald Ainscow and 30,000 to new employee.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.